Arctic Bioscience - Notice of Extraordinary General Meeting on 19 November 2024

05 Nov 2024 09:00 CET

An Extraordinary General Meeting in Arctic Bioscience AS will be held Tuesday 19
November 2024 at 10:00 (CET), as a digital meeting.

The agenda of the meeting is election of a new auditor for the Company. The
Company's elected auditor, Contabile, has informed the Board that they do not
have the capacity to continue their assignment responsibilities relating to the
audit of the Company. Based on a tender process PricewaterhouseCoopers (PWC) is
proposed by the Board to be elected as the Company's new auditor. PWC is
considered to handle the Company's future plans for development and will offer
good competence and availability. See attached notice for more information.

Shareholders are encouraged to cast their votes in advance of the General
Meeting or grant the Chair of the Board a proxy, with or without voting
instructions.

Deadline for registration of attendance, advance votes, proxy or instructions is
15 November 2024 at 16:00 (CET). For attendance to the live event, please follow
the instruction in the notice.

For further information, see the attached Notice of the Extraordinary General
Meeting, which can also be accessed from the company's website (https://arctic
-bioscience.com/investors/general-meetings/).

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

For more information, please contact:

Christer L. Valderhaug

CEO

Phone: +47 920 84 601

E-mail: christer@arctic-bioscience.com

Jone R. Slinning

CFO

Mobile: +47 948 75 469

E-mail: jone@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing
pharmaceutical and nutraceutical products based on unique bioactive marine
compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being
developed for treatment of patients with mild-to-moderate psoriasis. This is a
large patient group in need of new effective medicines with beneficial safety
profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as
well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and
highly relevant background.

More information:
Access the news on Oslo Bors NewsWeb site

631239_20241105_ABS_Notice_EGM_19_11_2024.pdf